Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.

By R. Marx, Y. Sawatari, M. Fortin, V. Broumand. Journal of oral and maxillofacial surgery, 2005

1,658 citations recorded by the source corpus.

Subfields: Oncology, Orthopedics and Sports Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/5094d11378a8a86f0ffecd3c28e7d8312c5ba2d5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Kalmar
2. J. Hellstein

Citations in the corpus

• Bisphosphonates: Mechanism of Action and Role in Clinical Practice (2008, neutral): “115,116 Whether concomitant chemotherapy or glucocorticoid use leads to an increased risk of ONJ is unknown.”
• Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws (2006, background): “, 2005 (27) 119 NS NS Myeloma (n 62) Breast cancer (n 50) Prostate cancer (n 4) Osteoporosis (n 3) Mandible (n 81) Maxilla (n 33) Both (n 5) 55 (46) Zoledronic acid (n 48) Pamidronate and zoledronic acid (n 36) Pamidronate (n 32) Alendronate (n 3)”
• Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research (2007, neutral): “P (5) A + P (1) Max (5) Marx et al.((23)) 3 O (3) A (3) Marunick et al.”